Cabo/Ifos in relapsed/refractory sarcomas (CaIRS trial)
Contact
Description
This study enrolls patients between 5 and 40 years of age with a diagnosis of any sarcoma that has progressed on or relapsed after upfront initial therapy. The purpose of this study is to find the best dose of a drug called cabozantinib ("the study drug") to give to patients in combination with a routine chemotherapy drug called ifosfamide.
Eligibility and criteria
IRB Number:
22-019876
Eligible age range:
Clinical trial phase:
Phase I
Official title:
What to expect
As a participant in the research, you will:
- Take cabozantinib (the study drug) by mouth once a day, in combination with routine chemotherapy drug ifosfamide given intravenously on days 1-5 of each cycle
- Complete frequent clinic visits at CHOP Philadelphia campus
- Have frequent blood tests
- Have EKGs and echocardiograms for clinical care purposes
- Have periodic imaging performed as part of your regular cancer care to evaluate your response to treatment
- Have research genetic tests (if not previously done clinically)
- Submit leftover tissue samples to the study repository
- Have fresh tissue samples collected (if you have a routine biopsy)
Related specialties
Related conditions
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.